Orforglipron / Foundayo in the United States
FOUNDAYO received FDA approval on April 1, 2026 under NDA 220934 for a defined adult weight-management population. The approval belongs to the exact tablets, label, manufacturer, prescription product, and US supply record. It does not transfer to a powder, research listing, imported presentation, or online product using the orforglipron name.
- Evidence lane
- FDA-approved medicine
- Global identity
- FDA-approved US medicine with country-specific status elsewhere